Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

Br J Haematol. 2021 Jul;194(1):e48-e51. doi: 10.1111/bjh.17448. Epub 2021 Jun 10.

Authors

Philippe Moreau¹, Razi Ghori², Mohammed Farooqui², Patricia Marinello², Jesus San Miguel³

Affiliations

¹ Department of Hematology, University Hospital Hotel-Dieu, Nantes, France.
² Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
³ Department of Clinical and Translational Medicine, Clinical Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

No abstract available

Keywords: immunotherapy; multiple myeloma; oncology.

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acute Kidney Injury / chemically induced
Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chemical and Drug Induced Liver Injury / etiology
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Female
Humans
Hypopituitarism / chemically induced
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Organ Failure / etiology
Oligopeptides / administration & dosage
Oligopeptides / adverse effects
Recurrence
Salvage Therapy*
Treatment Outcome
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Oligopeptides
carfilzomib
Dexamethasone
pembrolizumab